IMDZ Key Statistics, Chart & Performance
The current stock price of IMDZ is 5.85 null. In the past month the price increased by 0.34%. In the past year, price increased by 85.71%.
About IMDZ
Company Profile
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on the development of immune-based therapies based on its DCVex (TM) and GLAAS (TM) discovery platforms for cancer and other chronic conditions. Its product candidates in Phase I clinical trials comprise LV305, CMB305, and G305 for the treatment of solid tumor types, such as breast cancer, melanoma, non-small cell lung cancer, ovarian cancer, or sarcoma; and G100 for the treatment of patients with merkel cell carcinoma. Immune Design Corp. is headquartered in Seattle, Washington.
Company Info
Immune Design Corp.
1616 EASTLAKE AVENUE EAST SUITE 310
SEATTLE WA 98102
CEO: Carlos Paya
Phone: 206-682-0645
Immune Design Corp. / IMDZ FAQ
Can you describe the business of Immune Design Corp.?
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on the development of immune-based therapies based on its DCVex (TM) and GLAAS (TM) discovery platforms for cancer and other chronic conditions. Its product candidates in Phase I clinical trials comprise LV305, CMB305, and G305 for the treatment of solid tumor types, such as breast cancer, melanoma, non-small cell lung cancer, ovarian cancer, or sarcoma; and G100 for the treatment of patients with merkel cell carcinoma. Immune Design Corp. is headquartered in Seattle, Washington.
What is the stock price of Immune Design Corp. today?
The current stock price of IMDZ is 5.85 null.
Does IMDZ stock pay dividends?
IMDZ does not pay a dividend.
What is the ChartMill rating of Immune Design Corp. stock?
IMDZ has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the PE ratio for IMDZ stock?
Immune Design Corp. (IMDZ) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.15).
Would investing in Immune Design Corp. be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on IMDZ.
Can you provide the market cap for Immune Design Corp.?
Immune Design Corp. (IMDZ) has a market capitalization of 282.94M null. This makes IMDZ a Micro Cap stock.
IMDZ Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to IMDZ. When comparing the yearly performance of all stocks, IMDZ is one of the better performing stocks in the market, outperforming 99.57% of all stocks.
IMDZ Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IMDZ. While IMDZ has a great health rating, there are worries on its profitability.
IMDZ Financial Highlights
Over the last trailing twelve months IMDZ reported a non-GAAP Earnings per Share(EPS) of -1.15. The EPS increased by 46.01% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -2493.53% | ||
| ROA | -54.24% | ||
| ROE | -59.52% | ||
| Debt/Equity | 0 |